2629 Townsgate Road
Suite 215
Westlake Village, CA 91361
United States
818 597 7552
https://www.rebus-corp.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 1
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Raul Silvestre Esq. | CEO, CFO, President, Principal Accounting Officer & Director | N/D | N/D | 1971 |
Dr. John T. Isaacs Ph.D. | Co-Founder, Chairman of Scientific Advisory Board & Chief Scientific Advisor | N/D | N/D | N/D |
Dr. Samuel R. Denmeade M.D. | Co-Founder, Chief Clinical Advisor and Member of Scientific Advisory Board | N/D | N/D | N/D |
Rebus Holdings, Inc., together with its subsidiaries, focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. Rebus Holdings, Inc. was incorporated in 2003 and is based in Westlake Village, California.
L'ISS Governance QualityScore di Rebus Holdings, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.